Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Cancer incidence in relatives of British Fanconi Anaemia patients

Authors: Marc Tischkowitz, Douglas F Easton, Jan Ball, Shirley V Hodgson, Christopher G Mathew

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Fanconi anemia (FA) is an autosomal recessive DNA repair disorder with affected individuals having a high risk of developing acute myeloid leukaemia and certain solid tumours. Thirteen complementation groups have been identified and the genes for all of these are known (FANCA, B, C, D1/BRCA2, D2, E, F, G, I, J/BRIP1, L, M and N/PALB2). Previous studies of cancer incidence in relatives of Fanconi anemia cases have produced conflicting results. A study of British FA families was therefore carried out to investigate this question, since increases in cancer risk in FA heterozygotes would have implications for counselling FA family members, and possibly also for the implementation of preventative screening measures in FA heterozygotes.

Methods

Thirty-six families took part and data was collected on 575 individuals (276 males, 299 females), representing 18,136 person years. In this cohort, 25 males and 30 females were reported with cancer under the age of 85 years, and 36 cancers (65%) could be confirmed from death certificates, cancer registries or clinical records.

Results

A total of 55 cancers were reported in the FA families compared to an estimated incidence of 56.95 in a comparable general population cohort, and the relative risk of cancer was 0.97 (95% C.I. = 0.71–1.23, p = 0.62) for FA family members. Analysis of relative risk for individual cancer types in each carrier probability group did not reveal any significant differences with the possible exception of prostate cancer (RR = 3.089 (95% C.I. = 1.09 – 8.78; Χ2 = 4.767, p = 0.029).

Conclusion

This study has not shown a significant difference in overall cancer risk in FA families.
Literature
1.
go back to reference Heim RA, Lench NJ, Swift M: Heterozygous manifestations in four autosomal recessive human cancer-prone syndromes: ataxia telangiectasia, xeroderma pigmentosum, Fanconi anemia, and Bloom syndrome. Mutat Res. 1992, 284 (1): 25-36.CrossRefPubMed Heim RA, Lench NJ, Swift M: Heterozygous manifestations in four autosomal recessive human cancer-prone syndromes: ataxia telangiectasia, xeroderma pigmentosum, Fanconi anemia, and Bloom syndrome. Mutat Res. 1992, 284 (1): 25-36.CrossRefPubMed
2.
go back to reference Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF: Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005, 97 (11): 813-822.CrossRefPubMed Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF: Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005, 97 (11): 813-822.CrossRefPubMed
3.
go back to reference Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006, 38 (8): 873-875. 10.1038/ng1837.CrossRefPubMed Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006, 38 (8): 873-875. 10.1038/ng1837.CrossRefPubMed
4.
go back to reference Taniguchi T, D'Andrea AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006, 107 (11): 4223-4233. 10.1182/blood-2005-10-4240.CrossRefPubMed Taniguchi T, D'Andrea AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006, 107 (11): 4223-4233. 10.1182/blood-2005-10-4240.CrossRefPubMed
5.
go back to reference Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ: Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair. Cell. 2007 Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ: Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair. Cell. 2007
6.
go back to reference Tischkowitz M, Dokal I: Fanconi anaemia and leukaemia – clinical and molecular aspects. Br J Haematol. 2004, 126 (2): 176-191. 10.1111/j.1365-2141.2004.05023.x.CrossRefPubMed Tischkowitz M, Dokal I: Fanconi anaemia and leukaemia – clinical and molecular aspects. Br J Haematol. 2004, 126 (2): 176-191. 10.1111/j.1365-2141.2004.05023.x.CrossRefPubMed
7.
go back to reference Swift M: Fanconi's Anaemia in the genetics of neoplasia. Nature. 1971, 230 (5293): 370-373. 10.1038/230370a0.CrossRefPubMed Swift M: Fanconi's Anaemia in the genetics of neoplasia. Nature. 1971, 230 (5293): 370-373. 10.1038/230370a0.CrossRefPubMed
8.
go back to reference Swift M, Caldwell RJ, Chase C: Reassessment of cancer predisposition of Fanconi anemia heterozygotes. J Natl Cancer Inst. 1980, 65 (5): 863-867.PubMed Swift M, Caldwell RJ, Chase C: Reassessment of cancer predisposition of Fanconi anemia heterozygotes. J Natl Cancer Inst. 1980, 65 (5): 863-867.PubMed
9.
go back to reference Potter NU, Sarmousakis C, Li FP: Cancer in relatives of patients with aplastic anemia. Cancer Genet Cytogenet. 1983, 9 (1): 61-65. 10.1016/0165-4608(83)90025-0.CrossRefPubMed Potter NU, Sarmousakis C, Li FP: Cancer in relatives of patients with aplastic anemia. Cancer Genet Cytogenet. 1983, 9 (1): 61-65. 10.1016/0165-4608(83)90025-0.CrossRefPubMed
10.
go back to reference Mathew CG: Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006, 25 (43): 5875-5884. 10.1038/sj.onc.1209878.CrossRefPubMed Mathew CG: Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006, 25 (43): 5875-5884. 10.1038/sj.onc.1209878.CrossRefPubMed
11.
go back to reference Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, Dev Batish S, Morales J, Schindler D, Hanenberg H, Hromas R, Levran O, Auerbach AD: Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res. 2007, 67 (19): 9591-9596. 10.1158/0008-5472.CAN-07-1501.CrossRefPubMedPubMedCentral Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, Dev Batish S, Morales J, Schindler D, Hanenberg H, Hromas R, Levran O, Auerbach AD: Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res. 2007, 67 (19): 9591-9596. 10.1158/0008-5472.CAN-07-1501.CrossRefPubMedPubMedCentral
12.
go back to reference WHO: The International Classification of Disease and Health Related Problems. 1992, 10 WHO: The International Classification of Disease and Health Related Problems. 1992, 10
13.
go back to reference Coleman MP, Hermon C, A D: Person-years (PYRS) – a fortran program for cohort study analysis. International Agency for Research on Cancer internal report no. 89/006. 1989, IARC, Lyon Coleman MP, Hermon C, A D: Person-years (PYRS) – a fortran program for cohort study analysis. International Agency for Research on Cancer internal report no. 89/006. 1989, IARC, Lyon
14.
go back to reference Easton D: Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999, 91 (15): 1310-1316. 10.1093/jnci/91.15.1310.CrossRef Easton D: Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999, 91 (15): 1310-1316. 10.1093/jnci/91.15.1310.CrossRef
15.
go back to reference Dempster AP, Laird NM, Rubin DB: Maximum likelihood from incomplete data via the EM algorithm (with discussion). J Roy Statist Soc Series B. 1977, 39: 1-38. Dempster AP, Laird NM, Rubin DB: Maximum likelihood from incomplete data via the EM algorithm (with discussion). J Roy Statist Soc Series B. 1977, 39: 1-38.
16.
go back to reference Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006, 38 (11): 1239-1241. 10.1038/ng1902.CrossRefPubMed Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006, 38 (11): 1239-1241. 10.1038/ng1902.CrossRefPubMed
17.
go back to reference Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R: A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007, 446 (7133): 316-319. 10.1038/nature05609.CrossRefPubMed Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R: A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007, 446 (7133): 316-319. 10.1038/nature05609.CrossRefPubMed
18.
go back to reference Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007, 39 (2): 165-167. 10.1038/ng1959.CrossRefPubMed Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007, 39 (2): 165-167. 10.1038/ng1959.CrossRefPubMed
19.
go back to reference Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD: Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA. 2007, 104 (16): 6788-6793. 10.1073/pnas.0701724104.CrossRefPubMedPubMedCentral Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD: Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA. 2007, 104 (16): 6788-6793. 10.1073/pnas.0701724104.CrossRefPubMedPubMedCentral
20.
go back to reference Patel KJ: Fanconi anemia and breast cancer susceptibility. Nat Genet. 2007, 39 (2): 142-143. 10.1038/ng0207-142.CrossRefPubMed Patel KJ: Fanconi anemia and breast cancer susceptibility. Nat Genet. 2007, 39 (2): 142-143. 10.1038/ng0207-142.CrossRefPubMed
21.
go back to reference Seal S, Barfoot R, Jayatilake H, Smith P, Renwick A, Bascombe L, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N: Evaluation of Fanconi Anemia Genes in Familial Breast Cancer Predisposition. Cancer Res. 2003, 63 (24): 8596-8599.PubMed Seal S, Barfoot R, Jayatilake H, Smith P, Renwick A, Bascombe L, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N: Evaluation of Fanconi Anemia Genes in Familial Breast Cancer Predisposition. Cancer Res. 2003, 63 (24): 8596-8599.PubMed
Metadata
Title
Cancer incidence in relatives of British Fanconi Anaemia patients
Authors
Marc Tischkowitz
Douglas F Easton
Jan Ball
Shirley V Hodgson
Christopher G Mathew
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-257

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine